GCJ904 (Phase I)

Investigator physician: Dr Caroline Boursier

A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [¹⁷⁷Lu]Lu-DFC413 and safety and imaging properties of [⁶⁸Ga]Ga-NNS309 in patients with solid tumors

Solid tumors:
- Locally advanced or metastatic PDAC,
- NSCLC,
- HR+/HER2- ductal and lobular breast cancer,
- Triple-negative breast cancer,
- CRC and soft tissue sarcoma

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [¹⁷⁷Lu]Lu-DFC413 and the safety of [⁶⁸Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC), colorectal cancer (CRC), and soft tissue sarcoma (STS).

[⁶⁸Ga]Ga-NNS309
[¹⁷⁷Lu]Lu-DFC413
Study status: Recruiting
Clinical Trial number: NCT07261631
Funding: